Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.

Khalis MustafayevVincent MalletHarrys A Torres

Published in: Journal of immunotherapy and precision oncology (2024)

Chronic HBV or HCV infection should not be considered a contraindication for ICI therapy. Specific risk assessment, monitoring, and management strategies are necessary to reduce the risk of ICI-related liver injury in patients with cancer and chronic HBV or HCV infection.

Keyphrases

hepatitis b virus
hepatitis c virus
liver injury
drug induced
human immunodeficiency virus
risk assessment
liver failure
stem cells
cell therapy
replacement therapy